Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus EXEM FOAM KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus EXEM FOAM KIT.
ALA-SCALP vs EXEM FOAM KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
The active ingredient in EXEM FOAM KIT is diclofenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
Topical application of a 5% solution to the scalp twice daily.
Apply to affected area twice daily. Exemestane is an aromatase inhibitor; this is a topical formulation.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal elimination half-life is approximately 5–6 hours in patients with normal renal function; prolonged in hepatic impairment.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Primarily fecal via biliary elimination (>90% as unchanged drug and metabolites); renal excretion accounts for <10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid